- Journal Details
- Format
- Journal
- First Published
- 08 Aug 2013
- Publication timeframe
- 4 times per year
- Languages
- English
Large clinical laboratories often rely on multiple chemistry analyzers. However, when a new analyzer is introduced, the laboratory must establish whether the old and new methods are comparable and can be used interchangeably. In this study, we compared the newly introduced Atellica CH930 chemistry analyzer with the already established Architect ci4100 and Cobas 6000 c501 from our laboratory.
Patient samples were randomly selected from daily routine testing and a total of 22 analytes were investigated. Total error (TEobs) between test (Atellica) and comparative (Architect and Cobas) methods was calculated at relevant medical decision levels (MDL). For demonstrative purposes, the assessment of method comparability was based on three different criteria: allowable total error (TEa) derived from biological variation (BV), CLIA proficiency testing criteria for acceptable analytical performance, and CLIA-calculated Sigma metrics. These sets of analytical performance specifications were also compared, and their strengths and limitations are discussed in this paper.
Performance of Atellica CH930 against Architect ci4100 was acceptable or nearly acceptable at 82%, 95%, and 64% of the 22 investigated MDLs across 9 analytes, according to BV-TEa, CLIA-TEa, and CLIA-calculated Sigma metrics, respectively. Similarly, performance of Atellica CH930 against Cobas 6000 c501 was acceptable or nearly acceptable at 61%, 93%, and 63% of the 54 investigated MDLs across 22 analytes, according to BV-TEa, CLIATEa, and CLIA-calculated Sigma metrics, respectively. However, method comparability should not be evaluated by a “one size fits all” approach as some analytes require different criteria of acceptability, ideally based on medically allowable error and clinical outcome.
Cell Cycle Regulatory CCND1 G870A Gene Polymorphism and Periodontitis-Induced Oral Cancer: A Risk Analysis Atellica CH 930 chemistry analyzer versus Cobas 6000 c501 and Architect ci4100 - a multi-analyte method comparison Agreement between two diagnostic methods for COVID-19: preliminary data from a Brazilian clinical laboratory Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancerValues of serum PCT, suPAR combined with severity scores for evaluating prognosis of septic shock patients Circulating amino acids as fingerprints of visceral adipose tissue independent of insulin resistance: a targeted metabolomic research in women Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia COVID-19 associated coagulopathy is correlated with increased age and markers of inflammation response VEGF-C and podoplanin, as biomarkers of sepsis. An experimental study Acquired Angioedema Due to C1 inhibitor Deficiency Caused by Non-Hodgkin Lymphoma in a Patient with Myasthenia Gravis